Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

2.1K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
2.1K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.8K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.8K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

641
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
641
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

386
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
386
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

635
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
635
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

761
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
761

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hypertensive disorders in women with peripartum cardiomyopathy: insights from the ESC EORP PPCM Registry.

European journal of heart failure·2021
Same author

Readmission following both cardiac and non-cardiac acute dyspnoea is associated with a striking risk of death.

ESC heart failure·2021
Same author

Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials.

American heart journal·2021
Same author

Rapid identification of bacteria from respiratory samples of patients hospitalized in intensive care units, with FilmArray Pneumonia Panel Plus.

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases·2021
Same author

Comparison of Circulating Immune Cells Profiles and Kinetics Between Coronavirus Disease 2019 and Bacterial Sepsis.

Critical care medicine·2021
Same author

A urinary peptidomic profile predicts outcome in SARS-CoV-2-infected patients.

EClinicalMedicine·2021
Same journal

Author's reply.

Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology·2015
Same journal

Author's reply.

Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology·2015
Same journal

Author's reply.

Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology·2015
Same journal

Valsartan after myocardial infarction.

Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology·2015
Same journal

Hypertension and valsartan.

Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology·2015
Same journal

Renal and metabolic effects of valsartan.

Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology·2015
See all related articles

Related Experiment Video

Updated: May 5, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.1K

Cardiohepatic interactions in heart failure

Mehmet Birhan Yılmaz1, Maria Nikolaou, Alexandre Mebazaa

  • 1Department of Cardiology, Faculty of Medicine, Cumhuriyet University, Sivas-Turkey; GREAT network. cardioceptor@gmail.com.

Anadolu Kardiyoloji Dergisi : AKD = the Anatolian Journal of Cardiology
|November 21, 2013
PubMed
Summary

No abstract available in PubMed .

Related Experiment Videos

Last Updated: May 5, 2026

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.1K